<?xml version="1.0" encoding="UTF-8"?>
<p>To date, the mechanism and the molecular basis responsible for structural, biochemical, and functional changes occurring in glaucomatous TM are poorly understood [
 <xref ref-type="bibr" rid="CR26">26</xref>, 
 <xref ref-type="bibr" rid="CR27">27</xref>]. Several studies have been performed to identify systemic and local biochemical risk factors and some novel protein/antibody profiles have been prospected as potential targets to counteract the degenerative effects in POAG, in addition to the IOP [
 <xref ref-type="bibr" rid="CR3">3</xref>, 
 <xref ref-type="bibr" rid="CR4">4</xref>, 
 <xref ref-type="bibr" rid="CR28">28</xref>]. Recently, the protein microarray approach has highlighted, most resourceful than conventional approach, some candidates (biomarkers) for POAG, pertinent to routine diagnostic applications/monitoring of treatment efficacy or to target therapy [
 <xref ref-type="bibr" rid="CR18">18</xref>, 
 <xref ref-type="bibr" rid="CR29">29</xref>, 
 <xref ref-type="bibr" rid="CR30">30</xref>].
</p>
